secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023059
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M
--------------------------------------------------------------------------------

- Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).
- Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.
- FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.
- FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.
- Management highlights progress on ReNu program for knee osteoarthritis as key value driver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/orgo-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer